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ABSTRACT The intrinsic ﬂuorescence of smooth muscle myosin is sensitive to both nucleotide binding and hydrolysis. We
have examined this relationship by making MDE mutants containing a single tryptophan residue at each of the seven positions
found in the wild-type molecule. Previously, we have demonstrated that a conserved tryptophan residue (W512) is a major
contributor to nucleotide-dependent changes of intrinsic ﬂuorescence in smooth muscle myosin. In this study, an MDE
containing all the endogenous tryptophans except W512 (W512 KO-MDE) decreases in intrinsic ﬂuorescence upon nucleotide
binding, demonstrating that the intrinsic ﬂuorescence enhancement of smooth muscle myosin is not solely due to W512.
Candidates for the observed quench of intrinsic ﬂuorescence in W512 KO-MDE include W29 and W36. Whereas the intrinsic
ﬂuorescence of W36-MDE is only slightly sensitive to nucleotide binding, that of W29-MDE is paradoxically both quenched and
blue-shifted upon nucleotide binding. Steady-state and time-resolved experiments suggest that ﬂuorescence intensity changes
of W29 involve both excited-state and ground-state quenching mechanisms. These results have important implications for the
role of the N-terminal domain (residues 1–76) in smooth muscle myosin in the molecular mechanism of muscle contraction.
INTRODUCTION
Muscle contraction at the molecular level is driven by the
cyclic interaction of myosin, a ubiquitous motor protein, and
polymeric actin. Interdigitated ﬁlaments of myosin (thick
ﬁlaments) and actin (thin ﬁlaments) are arranged in parallel
and slide past one another, causing muscle shortening and
force production during contraction in striated muscle
(Huxley and Hansen, 1954; Huxley and Niedergerke,
1954). Filament sliding is thought to be achieved by
structural transitions in the globular regions of myosin,
known as cross-bridges, which extend away from the thick
ﬁlaments and interact with actin in a cyclic manner (Huxley,
1969). Structural transitions in myosin during muscle
contraction are believed to be mediated by chemical
transitions between intermediate states of the myosin
ATPase cycle, which have been well studied by transient
presteady-state and steady-state kinetic methods (reviewed
by Cooke, 1999; Geeves and Holmes, 1999) and summa-
rized below (Scheme I).
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SCHEME 1
Of particular importance to the current work is the
enhancement of intrinsic tryptophan ﬂuorescence in myosin
upon nucleotide binding (*) and hydrolysis of ATP (**),
which have been exploited to examine the rates of the
reaction steps in skeletal and smooth muscle myosin in both
the absence and presence of actin (Lymn and Taylor, 1971;
Bagshaw and Trentham, 1974; Bagshaw et al., 1974;
Marston and Taylor, 1980; Rosenfeld and Taylor, 1984;
Cremo and Geeves, 1998). In this scheme, myosin initially
binds ATP, resulting in the ﬁrst level of intrinsic tryptophan
ﬂuorescence enhancement (*). Next, the rapid and reversible
hydrolysis of ATP results in an additional enhancement of
intrinsic tryptophan ﬂuorescence (**). After hydrolysis,
inorganic phosphate and ADP are sequentially released, with
an associated decrease in intrinsic tryptophan ﬂuorescence at
each step. The phosphate-release step is rate-limiting and
shifts myosin from a weak to strong actin binding
conformation. It is this step that is believed to be associated
with force generation during muscle contraction. The
nucleotide-free complex (the ‘‘rigor’’ state) remains strongly
bound to actin until dissociated by the binding of ATP to
start a new contractile cycle. Therefore, although shown in
linear form, Scheme 1 describes the cyclic process of nu-
cleotide binding, hydrolysis, and product release by myosin.
The structural basis of these nucleotide-dependent in-
trinsic ﬂuorescence changes in myosin II has been previously
investigated in skeletal muscle (Park et al., 1997), smooth
muscle (Yengo et al., 1998, 2000), and the slime-mold
Dictyostelium discoideum (Batra and Manstein, 1999;
Kova´cs et al., 2002; Ma´lna´si-Csizmadia et al., 2000). In all
three isoforms, a single tryptophan residue (W501 in D.
discoideum nonmuscle myosin II, W510 in skeletal muscle
myosin, and W512 in smooth muscle myosin) has been
shown to be the largest contributor to the observed intrinsic
ﬂuorescence enhancement associated with nucleotide bind-
ing and/or hydrolysis. This conserved tryptophan is located
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in the relay loop, a region of myosin thought to be critically
involved in the conduction and ampliﬁcation of structural
changes at myosin’s active site to the lever arm and actin-
binding interface (reviewed by Houdusse and Sweeney,
2001). W501 has been shown to be the only tryptophan
residue to participate in the intrinsic ﬂuorescence enhance-
ment associated with the ATPase cycle in D. discoideum
nonmuscle myosin II (Batra and Manstein, 1999; Ma´lna´si-
Csizmadia et al., 2000). The situation has been demonstrated
to be more complicated in skeletal muscle myosin, with two
tryptophans unique to this isoform (W113 and W131)
potentially contributing to the overall enhancement of
intrinsic ﬂuorescence as well as W510 (Park and Burghardt,
2000; Kova´cs et al., 2002). It remains to be shown that W512
is uniquely sensitive to nucleotide binding and hydrolysis in
smooth muscle myosin.
In addition to W512’s sensitivity to nucleotide, we have
previously demonstrated that, although not responsive to
nucleotide binding, W546 is sensitive to actin binding
(Yengo et al., 1998), whereas tryptophans 441, 597, and 625
are all insensitive to both nucleotide and actin binding
(Yengo et al., 2000, 1998).The catalytic motor domain of
smooth muscle myosin (Fig. 1) contains seven tryptophan
residues (29, 36, 441, 512, 546, 597, and 625). Thus the
potential contributions of W29 and W36 to the observed
intrinsic ﬂuorescence changes in smooth muscle myosin
upon nucleotide binding and hydrolysis are as of yet
uncharacterized. In this study, we have generated a W512
knockout construct of smooth muscle myosin (W512 KO-
MDE) that contains the six endogenous tryptophans other
than W512, which was conservatively mutated to phenylal-
anine. We also constructed two mutants, W29-MDE and
W36-MDE, each of which contains a single endogenous
tryptophan at residue 29 or 36, respectively. The W512 KO-
MDE demonstrates a small quench in the presence of
nucleotide. Therefore, the intrinsic ﬂuorescence enhance-
ment of smooth muscle myosin is not solely due to the
conserved tryptophan residue (W512) that resides in the
relay loop. Subsequently, we investigated the possible
contributions to the intrinsic ﬂuorescence enhancement of
smooth muscle myosin by W29 and W36, which have not
been examined directly before. Both residues, which reside
near the SH3 domain at the N-terminus of the smooth muscle
myosin heavy chain and are unique to this isoform, are
sensitive to nucleotide binding, albeit less than W512 in the
relay loop.
METHODS
Mutagenesis
Generation of the WT-MDE and W512-MDE constructs was previously
described (Yengo et al., 2000). The W512 KO-MDE construct, in which
W512 was conservatively replaced with phenylalanine, was generated by
PCR-mediated site-directed mutagenesis from a cDNA of smooth muscle
myosin heavy chain containing the motor domain and essential light chain
binding regions (residues 1–819, kindly provided by Kathleen M. Trybus,
University of Vermont).We also constructed twomutants containing a single
tryptophan, W29-MDE and W36-MDE. Beginning with a Null-MDE
construct (Yengo et al., 2000) in which all the endogenous tryptophans had
been replaced with phenylalanine or methionine, the W29 was restored to
create W29-MDE, or the W36 was restored for the W36-MDE construct. All
PCR-ampliﬁed construct sequences were conﬁrmed by the University of
Vermont DNA Sequencing Facility.
Protein expression and puriﬁcation
MDE cDNA was cloned into the pVL-1392-NE baculovirus transfer vector
(Invitrogen, Carlsbad, CA) containing a FLAG afﬁnity tag (DYKDDDDK),
transfected into Sf9 cells with Baculo-Gold (BD Biosciences Pharmingen,
Boston, MA), ampliﬁed, then expressed and puriﬁed on a FLAG afﬁnity
column (Sigma, St. Louis, MO) to yields of 1–3 mg per 1 3 109 Sf9 cells.
The ﬁnal product was stored in MDE buffer containing 10 mM MOPS,
20 mM KCl, 1 mM EGTA, 1 mM NaN3, and 1 mM DTT, pH 7.4, RT.
Functional assays
Actin-activated ATPase rates were determined by an enzyme-linked assay as
previously described (Furch et al., 1998; De la Cruz et al., 2000) in
a modiﬁed ATPase buffer (10 mMMOPS, 25 mMKCl, 2 mMMgCl2, 1 mM
EGTA, 1 mM DTT, pH 7.0, 25C). Puriﬁed MDE was assayed at
a concentration of 1–4 mM in the presence of 0–120 mM actin. The average
actin-activated ATPase rates of the MDE preparation were plotted as
a function of actin concentration and ﬁt with a nonlinear least-squares
method using OriginLab software (Northampton, MA). Values of Vmax and
KM were calculated using Michaelis-Menton kinetics.
Fluorescence measurements
Steady-state tryptophan ﬂuorescence measurements were made essentially
as described (Yengo et al., 2000) using a Quantamaster ﬂuorometer (Photon
Technology International, South Brunswick, NJ) equipped with a 75 or
150 W Xenon arc lamp as an excitation source, excitation/emission
monochrometers, and a WG320 cutoff emission ﬁlter. Tryptophan emis-
sion spectra were measured by exciting the sample at 295 nm and collecting
the emitted ﬂuorescence at 305–400 nm. Slit widths were set at a resolution
of 1–2 nm for excitation and 4–5 nm for emission. Fluorescence emission
FIGURE 1 Crystal structure of the smooth muscle myosin MDE construct
with the myosin heavy chain colored yellow (residues 1–819) and the
essential light chain colored orange. The seven endogenous tryptophans are
space ﬁlled and colored gray, and the N-terminal SH3 domain (residues 33–
76) adjacent to W29 and containing W36 is colored pink (Dominguez et al.,
1998).
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spectra were measured for each of the puriﬁed proteins in MDE buffer (10
mM MOPS, 20 mM KCl, 1 mM EGTA, 1 mM NaN3, 1 mM DTT, pH 7.4,
RT) in the presence of saturating amounts of ADP (20–200 mM) or ATP
(2 mM) as well as in the absence of nucleotide. All ﬂuorescence spectra
were corrected for Raman scatter and background ﬂuorescence.
Acrylamide quenching was used to determine the degree of solvent
exposure of W29 and W36 in the presence and absence of 2 mM ATP as
previously described (Yengo et al., 2000). The decrease in ﬂuorescence
intensity at the emission maximum (lmax) of the steady-state emission
spectrum was measured as a function of increasing acrylamide concen-
trations ([Q]). The ﬂuorescence intensity in the absence of quencher (F0)
divided by the ﬂuorescence intensity in the presence of quencher (F) was
used to quantify the relative change in ﬂuorescence from acrylamide
quenching (F0/F). F0/F was plotted as a function of [Q] and ﬁt to the Stern-
Volmer relationship, taking into account both static (V) and dynamic (KSV)
quenching constants: F0/F ¼ (1 1 KSV[Q])(expV[Q])(Eftink and Ghiron,
1976). The static quenching value, which determines the upward curvature
of the Stern-Volmer plot, was previously determined to be V ¼ 3.0 M1
(Yengo et al., 2000). Therefore, the dynamic quenching constant was
determined by ﬁtting the Stern-Volmer plots by a nonlinear least squares
method using OriginLab software. The bimolecular quenching constant was
calculated by normalizing the measured dynamic quenching constant to the
observed tryptophan average lifetime (kq ¼ Ksv/tavg).
Tryptophan lifetime measurements in the presence and absence of
0.2 mM ADP or 2 mM ATP were measured with a Photon Technology
International (London, Canada) Laserstrobe system with a nitrogen-pumped
dye laser emitting at 590 nm and frequency doubled to 295 nm. Total
ﬂuorescence emission was detected through a WG320 cutoff ﬁlter using
a stroboscopic detection system with a time-delay gated photomultiplier
tube. The instrument response function was collected by determining the
peak time delay of light scattered at 295 nm by nonfat dry milk solids and
used to deconvolute the experimental time-resolved emission decays using
proprietary software from Photon Technology International. The data were
best ﬁt to a two-exponential decay. The time-resolved quantum yield was
calculated relative to the natural tryptophan lifetime (16 ns). Quantum yield
and bimolecular quenching constant calculations were made using an
amplitude weighted average lifetime value (tavg ¼ (t1 3 ampl1)/(ampl1 1
ampl2) 1 (t2 3 ampl2)/(ampl1 1 ampl2)).
Analysis of protein crystal structures
The three-dimensional structures of smooth muscle myosin MDE in the
presence of ADP  AlF4 (1BR1.pdb) and ADP  BeFx (1BR4.pdb) were
visualized and analyzed in terms of intramolecular distances and B-factor
values in Swiss-PDB Viewer (GalaxoSmithKline, Middlesex, UK). The
solvent-accessible surface areas of W29 and W36 were calculated using
a script in XPLOR (Molecular Simulations, San Diego, CA), which
describes the center of a spherical solvent molecule of radius 1.6 A˚ rolling
along the protein surface.
RESULTS
Functional assays
Actin-activated ATPase assays were used to access the
functionality of the expressed MDE constructs. In these
assays, the steady-state ATPase rate of each MDE construct
at various concentrations of actin (0–120 mM) was followed
by stopped ﬂow at 25C (De la Cruz et al., 2000; Furch et al.,
1998). The smooth muscle myosin WT-MDE construct
containing the seven endogenous tryptophans is compared to
the W512 KO-MDE mutant lacking W512, and the single
tryptophan containing W29-MDE and W36-MDE mutants.
The Michaelis-Menton constants of WT-MDE, W512 KO-
MDE, W29-MDE, and W36-MDE are presented in Table 1.
By this assay, these constructs all show enhanced ATPase
rates in the presence of actin, with Vmax values of 0.17 6
0.09 s1 for WT-MDE, 0.086 0.05 s1 for W512KO-MDE,
0.15 6 0.03 s1 for W29-MDE, and 0.48 6 0.28 s1 for
W36-MDE. The KM values are 63 6 15 mM, 35 6 40 mM,
26 6 17 mM, and 8 6 37 mM for WT-MDE, W512KO-
MDE, W29-MDE, and W36-MDE, respectively. Thus the
catalytic efﬁciencies (Vmax/KM) for WT-MDE, W512KO-
MDE, W29-MDE, and W36-MDE are 2.7 3 103 M1s1,
2.3 3 103 M1s1, 5.8 3 103 M1s1, and 6.0 3 104
M1s1, respectively.
Fluorescence enhancement
Smooth muscle myosin exhibits an increase in tryptophan
ﬂuorescence upon ATP binding (M*  ATP), followed by a
further enhanced tryptophan ﬂuorescent state (M** ADP.Pi)
upon ATP hydrolysis (Fig. 2) (Johnson and Taylor, 1978;
Rosenfeld and Taylor, 1984; Woodward et al., 1995; Cremo
and Geeves, 1998). We have previously demonstrated that
W512, a conserved tryptophan residue located in the relay
loop of smooth muscle myosin, undergoes a similar pattern of
intrinsic ﬂuorescence enhancement, only to a greater extent,
compared to the wild-type molecule (Yengo et al., 2000).
Therefore, to test the hypothesis that W512 uniquely
contributes to the observed intrinsic ﬂuorescence enhance-
ment upon nucleotide binding and hydrolysis in smooth
muscle myosin, we created a mutant construct containing six
of the seven tryptophan residues endogenous to the wild-type
molecule (at positions 29, 36, 441, 546, 597, and 625), lacking
only W512 (which was conservatively replaced with
phenylalanine). The percent enhancements and emission
maximum of steady-state tryptophan ﬂuorescence of the
nucleotide-containing complexes as compared to the nucle-
otide free (apo) states for each of our MDE constructs are
presented in Table 2. WT-MDE has previously been shown
to exhibit an intrinsic ﬂuorescence with enhancements of
12.16 0.0% in the presence of ADP and 18.46 0.0% during
TABLE 1 Actin-activated Mg-ATPase activity of wild-type
and mutant MDEs
Construct Vmax (s
1) KM (mM)
Catalytic
efﬁciency
Vmax/KM (M
1s1)
WT-MDE (5) 0.17 6 0.09 63 6 15 2.7 3 103
W512 KO-MDE (2) 0.08 6 0.05 35 6 40 2.3 3 103
W29-MDE (3) 0.15 6 0.03 26 6 17 5.8 3 103
W36-MDE (3) 0.48 6 0.28 8 6 37 6.0 3 104
Dependence of steady-state ATPase activity on actin concentration. Vmax
and KM values (mean 6 SD) were calculated by plotting actin-activated
ATPase rates as a function of actin concentration and ﬁtting the curves to
Michaelis-Menton kinetics. The number of times the experiment was
repeated is given in parentheses.
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steady-state hydrolysis of ATP, and W512-MDE has pre-
viously been shown to exhibit an intrinsic ﬂuorescence with
enhancements of 30.1 6 2.1% in the presence of ADP and
36.1 6 1.1% during steady-state hydrolysis of ATP, as
compared to the nucleotide-free state, respectively (Yengo
et al., 2000). In contrast, the W512 KO-MDE mutant
demonstrates a quenching of 2.9 6 1.7% in the presence
of ADP, and a further quench to 5.6 6 1.9% during the
steady-state hydrolysis of ATP, as compared to the nucleotide
free state, respectively (Fig. 2 A). In addition, the emission
peak maximum of W512 KO-MDE (334 6 2 nm) is almost
identical to that of WT-MDE (336 6 0 nm) (Yengo et al.,
2000). Thus, the decreased ﬂuorescence of W512 KO-MDE
indicates thatW512 is not the only tryptophan that contributes
to the observed changes in intrinsic ﬂuorescence upon
nucleotide binding and/or hydrolysis in smooth muscle
myosin. Furthermore, the other tryptophan residue(s) that
are sensitive to nucleotide binding and/or hydrolysis have an
opposing effect (i.e., a decrease of overall intrinsic ﬂuores-
cence intensity is observed) to that of W512.
We have previously demonstrated that four of the six
remaining tryptophans (at positions 441, 546, 597, and 625)
are not sensitive to nucleotide binding or hydrolysis, leaving
W29 and W36 as candidates for the quench in intrinsic
tryptophan ﬂuorescence observed upon nucleotide binding
in theW512KO-MDE construct. ResiduesW29 andW36 are
located adjacent to and within the SH3 domain (residues 33–
76) at the N-terminus of the molecule. Therefore, we have
generated two mutants of smooth muscle myosin in which all
the endogenous tryptophans are absent except either W29 or
W36. We examined the steady-state ﬂuorescence properties
of W29-MDE and W36-MDE in the presence of nucleotides
and compared these properties both qualitatively and
quantitatively to the nucleotide-free state and to WT-MDE
(Table 2, Fig. 2). The emission peak wavelength for W29 in
the nucleotide-free state (332 6 3) was blue-shifted 4 nm in
comparison to WT-MDE, showed an additional 4 nm blue
shift in the presence of ADP (3286 1), and an even greater 5
nm blue shift in the presence of ATP (3276 2) (Table 2, Fig.
2 B). The emission peak wavelength for W36-MDE (325 6
2) was blue-shifted 11 nm from WT-MDE, but like WT-
MDE, the emission maximum did not change in the presence
or absence of nucleotides (Table 2, Fig. 2 C). The tryptophan
ﬂuorescence of W29-MDE is quenched20.76 6.4% in the
presence of ADP and28.96 3.0% in the presence of ATP.
In contrast, W36-MDE tryptophan ﬂuorescence is quenched
only3.46 2.3% in the presence of ADP and7.76 0.8%
in the presence of ATP (Table 2, Fig. 2 C).
As seen above, the steady-state response of W29-MDE to
nucleotide binding exhibits both a decrease in ﬂuorescence
intensity and a blue shift in its emission maximum. The
presence of these two characteristics together is paradoxical,
since a blue shift is often indicative of a change in con-
formation resulting in a more hydrophobic environment,
whereas a decrease in ﬂuorescence is often indicative of
a conformational change resulting in a more hydrophilic
TABLE 2 Tryptophan ﬂuorescence enhancement relative to the nucleotide free state
Nucleotide complex WT-MDE* W512-MDE* W512 KO-MDE W29-MDE W36-MDE
Enhancement (%):
ADP 12.1 6 0.0 30.1 6 2.1 2.9 6 1.7 20.7 6 6.4 3.4 6 2.3
ATP 18.4 6 0.0 36.1 6 1.1 5.6 6 1.9 28.9 6 3.0 7.7 6 0.8
n ¼ 5 n ¼ 5 n ¼ 4 n ¼ 5 n ¼ 3
Emission max. (nm):
Apo 336 6 0 336 6 0 334 6 2 332 6 3 325 6 2
ADP 336 6 0 336 6 0 334 6 2 328 6 1 325 6 2
ATP 336 6 0 336 6 0 334 6 2 327 6 2 325 6 2
n ¼ 5 n ¼ 5 n ¼ 4 n ¼ 5 n ¼ 4
The mean 6 SD enhancement in the peak ﬂuorescence intensity of WT-MDE, W512-MDE, W512 KO-MDE, W29-MDE, and W36-MDE-MDE in the
presence of ADP or ATP are expressed relative to the nucleotide-free state. The peak emission wavelength6SD in the absence and presence of nucleotide is
also reported.
*Yengo et al. (2000).
FIGURE 2 Fluorescence emission spectra of W512
KO-MDE, W29-MDE, and W36-MDE. The steady-
state ﬂuorescence spectra in the presence of nucleotides
are compared to the nucleotide free environment (apo).
(A) The percent increase in peak ﬂuorescence of W512
KO-MDE in the presence of 200 mMADP is3% and
in the presence of 2 mM ATP is 6%. (B) The percent
increase in peak ﬂuorescence of W29-MDE in the
presence of 200 mMADP is21% and in the presence
of 2 mM ATP is 29%. The emission peak wavelength for W29 in the nucleotide-free state showed a 4 nm blue shift in the presence of ADP, and an even
greater 5 nm blue shift in the presence of ATP. (C) The percent increase in peak ﬂuorescence of W36-MDE in the presence of 200 mMADP is3% and in the
presence of 2 mM ATP is 8%. The emission maximum of W36 is not sensitive to nucleotide binding.
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environment, around the tryptophan residue. Acrylamide
quenching is dependent upon the number of collisions
between the tryptophan and acrylamide molecules in the
surrounding solvent. Thus the more solvent accessible the
tryptophan, themore easily it is quenched by interactionswith
acrylamide. We examined the solvent exposure of W29 and
W36 in different nucleotide states by acrylamide quenching
experiments. The Stern-Volmer relationship was used to
quantitatively assess the amount of acrylamide quenching
(Fig. 3). The Stern-Volmer constant of W36-MDE was not
dependent on nucleotide asKSV¼ 2.04M1 in the absence of
nucleotide andKSV¼ 2.17M1 in the presence of 2mMATP.
In contrast, the Stern-Volmer constant of W29-MDE de-
creased 32% from 6.79 M1 in the absence of nucleotide to
4.63 M1 in the presence of 2 mMATP. When normalized to
the average excited-state lifetime (tavg) (Fig. 4, Table 3), the
dynamic Stern-Volmer constant can be used to calculate the
underlying bimolecular quenching constant (kq ¼ KSV/tavg),
a measure of the collisional rate between the ﬂuorophore and
solvent quencher molecules. The bimolecular quenching
constants were determined to be 8.03 108M1s1 and 4.83
108 M1s1 for W29-MDE in the absence and presence of
ATP, respectively, and 2.8 3 108 M1s1 and 2.6 3 108
M1s1 for W36-MDE in the absence and presence of ATP,
respectively (Table 3). These data are consistent with the
conclusion thatW29 becomes less accessible to solvent in the
presence of ATP, whereas the accessibility of W36 is largely
unchanged. Thus, in agreementwith the observed steady-state
ﬂuorescence emission maxima data, the acrylamide quench-
ing results suggest that W29 is in a less polar, less solvent-
exposed environment in the nucleotide states that bindweakly
to actin (MATP and MADPPi) relative to the strongly
bound nucleotide free state of the ATPase cycle.
Proteins that display a blue-shifted emission spectrum are
expected to have higher steady-state ﬂuorescence intensities
or longer lifetimes based on the usual increase in quantum
yield when a ﬂuorophore is placed in a less polar environ-
ment. In addition to the steady-state ﬂuorescence character-
izations, we also determined the quantum yields of W29 and
W36 in the presence and absence of nucleotide by lifetime
analysis (tavg/t0), where the intrinsic lifetime (t0) is assumed
to be 16 ns (Lakowicz, 1983). The quantum yield of the
excited state of W29 is slightly greater in the nucleotide-free
state (0.15) than in the presence of either 200 mM ADP or
2 mM ATP (0.12). However, upon ATP binding the
difference in the excited-state quantum yield of W29
(20%) is smaller than the observed decrease in steady-state
ﬂuorescence intensity (29%), suggesting that the observed
quench in the presence of ATP is a consequence of both
ground-state and excited-state phenomena. Conversely, the
quantum yield of the excited state of W36 is unchanging
regardless of the nucleotide state, at 0.17 in the absence of
ATP and 0.18 in the presence of 2 mM ATP. Therefore, the
FIGURE 3 Acrylamide quenching of W36-MDE and W29-MDE in the
presence of 2 mM ATP or in the absence of nucleotide (apo). The relative
change in ﬂuorescence (F0/F) is plotted as a function of increasing
acrylamide (mM), and the data points are ﬁt to the Stern-Volmer relationship
(F0/F ¼ (1 1 KSV [Q])expV[Q], where KSV is the dynamic quenching
constant and V is the static quenching constant previously determined to be
3.0 M1 (Yengo et al., 2000)).
FIGURE 4 Time-resolved ﬂuorescence decays of W29-MDE and W36-
MDE in the absence (apo) and presence of 2 mMATP. Each trace represents
the average of eight data sets. The instrument response function (dotted line)
is the laser pulse proﬁle measured from a scattering solution in the sample
cuvette. Dashed lines are the best ﬁt to a two-exponential decay. W29-MDE
demonstrated a quench in ﬂuorescence intensity upon ATP addition,
whereas W36-MDE did not signiﬁcantly change in ﬂuorescence intensity
upon nucleotide addition. The measured average lifetimes are presented in
Table 3.
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observed quenching of W36 is most likely due to strictly
ground-state phenomena.
DISCUSSION
Much of the kinetic information about the ﬁrst two steps of
the skeletal and smooth muscle myosin II ATPase cycle,
ATP binding and hydrolysis, has been elucidated by
following changes in the intrinsic tryptophan ﬂuorescence,
which shows an enhancement upon ATP binding and
a further enhancement upon ATP hydrolysis (Johnson and
Taylor, 1978; Rosenfeld and Taylor, 1984; Woodward et al.,
1995; Cremo and Geeves, 1998). However, little is known
about the structural basis underlying these changes in
intrinsic tryptophan ﬂuorescence. To investigate such
structural changes, one must ﬁrst identify the tryptophans
responsible for the observed intrinsic ﬂuorescence signals.
We have previously demonstrated that W512 is one of the
tryptophan residues responsible for changes in intrinsic
ﬂuorescence during the ATPase cycle of smooth muscle
myosin (Yengo et al., 2000). In this study, we have
investigated whether tryptophan 512 is uniquely sensitive
to nucleotide binding and hydrolysis in smooth muscle
myosin. The W512 KO-MDE demonstrated a small quench
in tryptophan ﬂuorescence in the presence of nucleotide,
providing evidence that W512 is not uniquely sensitive in
smooth muscle myosin. Given that we have already shown
that the conserved tryptophans W441 and W597 (Yengo
et al., 2000), as well as the isoform speciﬁc tryptophans
W546 and W625 (Yengo et al., 1998), are not sensitive to
nucleotide binding and hydrolysis in smooth muscle
myosin,W29 and W36, both unique to smooth muscle
myosin, are likely candidates for the changes in intrinsic
ﬂuorescence observed upon nucleotide binding in W512
KO-MDE.
Functional properties of WT-, W512 KO-, W29-,
and W36-MDE
Michaelis-Menton kinetic constants for the actin-activated
ATPase activity of WT-MDE were previously reported
(Yengo et al., 2000) and repeated for this study. The W512
KO-MDE and W29-MDE constructs show reduced values of
Vmax relative to the WT-MDE molecule, whereas W36-MDE
shows an increased value of Vmax relative to WT-MDE
(Table 1). However, all four constructs (WT-MDE, W512
KO-MDE, W29-MDE, and W36-MDE) demonstrate a sig-
niﬁcant actin-activated ATPase activity, and all three
mutants show decreased KM values relative to WT-MDE.
Although the Vmax and KM values vary between the
constructs (Table 1), the catalytic efﬁciencies of WT-MDE,
W512 KO-MDE, and W29-MDE are comparable, whereas
the W36-MDE is;10-fold more efﬁcient than even the WT-
MDE. Likewise, Pi release is the rate-limiting step of the
ATPase for all of the smooth muscle myosin constructs used
in our studies (manuscript submitted). Thus, although the
mutant proteins may have small variations in rate or
equilibrium constants between speciﬁc states of the ATPase
cycle (M. van Duffelen, L. R. Chrin, and C. L. Berger, un-
published), the overall catalytic cycle is quite similar for all
the constructs of smooth muscle myosin used in this study.
Contribution of W29 and W36 to the overall
intrinsic ﬂuorescence changes in smooth
muscle myosin
As demonstrated previously (Yengo et al., 2000) and in this
work, W512 is one of the major contributors to changes in
intrinsic ﬂuorescence during the ATPase cycle of smooth
muscle myosin. The corresponding residues in the relay
loops of myosin II from skeletal muscle (W510, (Park and
Burghardt, 2000)) and the slime mold D. discoideum (W501,
(Batra and Manstein, 1999; Ma´lna´si-Csizmadia et al., 2000))
have also been shown to be the primary contributors to the
nucleotide-dependent changes in intrinsic tryptophan ﬂuo-
rescence in these isoforms, and in the case of myosin II from
D. discoideum, W501 has been shown to be the only
endogenous tryptophan in the motor domain that is sensitive
to nucleotide binding (Ma´lna´si-Csizmadia et al., 2000).
Likewise, W510 has been proposed to be the sole contributor
to the nucleotide-dependent changes in tryptophan ﬂuores-
cence for skeletal muscle myosin (Park and Burghardt,
2000). However, when two tryptophans are introduced into
the D. discoideum motor domain at positions 113 and 131,
which correspond to those uniquely present in vertebrate
skeletal muscle myosin, these residues also contribute to the
observed nucleotide dependent changes in intrinsic ﬂuores-
cence for that isoform, albeit to a lesser extent than W510
(Kova´cs et al., 2002). Thus, whereas the conserved
tryptophan residue at position 512 of the relay loop in
smooth muscle myosin appears to be a major contributor to
TABLE 3 Spectroscopic data
Nucleotide
complex
Lifetime
tavg (ns)
Quantum
yield V
Stern-Volmer
constant KSV (M
1)
Bimolecular
quenching
constant
kq (M
1s1)
W29-MDE
Apo 2.4 0.15 6.79 8.0 3 108
ADP 2.0 0.12 n.d. n.d.
ATP 2.0 0.12 4.63 4.8 3 108
W36-MDE
Apo 2.7 0.17 2.04 2.8 3 108
ATP 2.9 0.18 2.17 2.6 3 108
The time-resolved quantum yield (V), Stern-Volmer constant (KSV), and
bimolecular quenching constants (kq) are reported for W29-MDE and W36-
MDE-MDE in the presence of ADP, ATP, or in the nucleotide-free state.
Weighted average ﬂuorescence lifetimes (tavg) are determined by the
equation [t1 3 A1/(A1 1 A2)] 1 [t2 3 A2/(A1 1 A2)]. The quantum yield is
reported relative to the natural tryptophan lifetime (16 ns). The bimolecular
quenching constant (kq) is given by Ksv/tavg. Standard errors in the ﬁtted
parameters were ,25% of the values given. Parameters deduced from
experimental runs (n ¼ 3–4) agreed within 15% of the values given.
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nucleotide-dependent changes in intrinsic ﬂuorescence as in
all isoforms of myosin, isoform-speciﬁc differences also
exist resulting from the presence of unique nonconserved
tryptophans in other conformationally sensitive regions of
the myosin molecule. Such isoform-speciﬁc tryptophan
residues may play a role in the response of smooth muscle
myosin in nucleotide binding and hydrolysis, and provide
new information regarding structural changes associated
with speciﬁc steps of the ATPase cycle.
Unlike W512-MDE, which shows a large increase in
intrinsic ﬂuorescence in response to both ADP (30%) and
ATP (36%) when compared to the nucleotide free state
(Yengo et al., 2000), W512 KO-MDE shows a small
decrease in intrinsic ﬂuorescence in response to both ADP
(3%) and ATP (6%) when compared to the nucleotide
free state. This provides evidence for the existence of
intrinsic ﬂuorescence contributions from the previously
uninvestigated tryptophan residues, W36 and W29 in
smooth muscle myosin, given that W441, W546, W597,
and W625 have all been previously shown to be insensitive
to nucleotide binding (Yengo et al., 2000). We found that
W36-MDE also shows a small decrease in intrinsic
ﬂuorescence in response to both ADP (3%) and ATP
(8%) when compared to the nucleotide free state. Thus,
given these small changes, in the presence of the other six
endogenous tryptophans, W36 is unlikely to contribute
signiﬁcantly to the observed nucleotide-dependent changes
in intrinsic ﬂuorescence of the wild-type molecule. However,
W29-MDE exhibits a large quench in intrinsic ﬂuorescence
in response to both ADP (21%) and ATP (29%), and
therefore is likely to contribute substantially to the
nucleotide-dependent intrinsic ﬂuorescence changes ob-
served in both the WT- and W512 KO-MDE molecules.
Thus, the intrinsic ﬂuorescence of tryptophans W512, W29,
and W36 are all sensitive to nucleotide binding in smooth
muscle myosin.
Structural basis for nucleotide-dependent
changes in W29 and W36 intrinsic ﬂuorescence
The decrease in ﬂuorescence intensity is accompanied by
a spectral blue shift upon nucleotide binding in W29-MDE
(Table 2, Fig. 2). A spectral blue shift is often indicative of
a conformational change to a more hydrophobic environ-
ment, whereas a decrease in ﬂuorescence intensity is often
indicative of a conformational change to a more hydrophilic
environment. This paradox can be resolved by collisional
quenching experiments, which are a measure of the solvent
accessibility of the ﬂuorophore. The Stern-Volmer and
bimolecular quenching constants of W29-MDE both de-
crease upon ATP binding as compared to the apo state (Table
3, Fig. 3), consistent with the observed blue shift of W29
ﬂuorescence upon nucleotide binding. These results indicate
a decrease in solvent exposure of W29, and thus a decrease
in solvent relaxation of the tryptophan residue in the more
buried state. There is also a small decrease in ﬂuorescence
intensity without a spectra shift upon ATP binding for W36
(Table 2, Fig. 2). The Stern-Volmer constants and the
bimolecular quenching constants are not nucleotide-de-
pendent (Table 3, Fig. 3), therefore the solvent accessibility
of W36 does not change upon ATP binding. The relatively
low Stern-Volmer and bimolecular quenching constants, as
well as the relatively blue-shifted emission maxima, suggest
that both W29 and W36 are predominantly buried in the
smooth muscle myosin molecule. Analysis of the smooth
muscle myosin MDE crystal structures in the presence of
AlF4 and BeFx show that the W29 and W36 indole rings are
39% and 1.5% exposed to the solvent, respectively.
Interestingly, the B-factor for the W29 residue is relatively
high, suggesting heterogeneity in the position of this side
chain despite being largely buried in the protein structure,
whereas the B-factor for the W36 residue is relatively low as
expected. These results are consistent with our observations
that both tryptophan residues are not easily quenched by
solvent interactions, with W36 being more protected than
W29. The increased dynamics of the W29 side chain may
reﬂect the ability of this region of the molecule, a loosely
structured loop, to adopt multiple conformations. Clearly,
our data strongly support such a possibility.
Decreases in steady-state ﬂuorescence emission can arise
from a combination of ground- and excited-state quench-
ing mechanisms, whereas time-resolved emission decays are
sensitive only to excited-state relaxation phenomena.
Therefore, we also measured the ﬂuorescence lifetimes of
both W29 and W36 (Table 3). Consistent with the steady-
state observations, the number of excited-state tryptophans
decreases slightly for W36 and decreases substantially for
W29, as indicated by the peak intensity of the ﬂuorescence
emission decay proﬁle (Fig. 4). W36-MDE time-resolved
ﬂuorescence emission decays are not nucleotide-dependent
(Table 3), indicating that the ﬂuorescence of W36 is
quenched predominantly by a ground-state mechanism upon
nucleotide binding. In contrast, time-resolved quantum yield
determinations of W29 show a 20% decrease upon
nucleotide binding, but no difference is observed whether
the nucleotide is ADP or ATP (Table 3). This result is
consistent with an excited-state mechanism responsible for
the steady-state ﬂuorescence quench observed upon nucle-
otide binding (;20%). The additional ;10% decrease in
intrinsic ﬂuorescence observed under steady-state conditions
upon the binding of ATP relative to ADP by W29-MDE
appears to involve an additional ground-state quenching
mechanism as there is no observed difference in the excited-
state quantum yield. The extension of this is that the ATP
binding event alters the W29 ground state so that it is less
excitable than in the presence of ADP.
The indole ring of tryptophan has the potential to be
quenched by neighboring residues, and the degree of
quenching is dependent on both the orientation and distance
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between the two side chains. Within the sequence surround-
ing the W29 tryptophan in both the ADP  AlF4 (Fig. 5) and
ADP  BeFx crystal structures (Dominguez et al., 1998), K32
is a charged residue within 4–5 A˚ of the face of the indole
ring of W29. Therefore, one possibility is that the observed
quench in W29 ﬂuorescence may be due to the interaction of
K32 with the pi electrons of the indole ring of W29. Thus,
W29 and K32 may alter their orientation and molecular
distance with respect to one another, resulting in different
levels of quenching in different states of the ATPase cycle.
Alternatively, other residues may be involved since W29 is
located in a conformationally sensitive loop of the smooth
muscle myosin molecule. It will be interesting to examine
other smooth muscle myosin structures as they become
available for possible interactions between W29 and other
amino acid side chains such as K32.
Functional implications for nucleotide-dependent
changes in W29 and W36 intrinsic ﬂuorescence
W36 is located within the smooth muscle myosin N-terminal
SH3 domain, whereas W29 is located in an adjacent loosely
structured loop. The SH3 domain is an antiparallel b-barrel in
the N-terminus comprising residues 33–76. One of the ﬁrst
indications of nucleotide-dependent structural changes in this
region of the molecule for either skeletal or smooth muscle
myosin was the observation that R23 in skeletal S1 is cleaved
by trypsin in the presence of ATP but not in the absence
of ATP (Pinter et al., 1986). Subsequently, cryoelectron
microscopy has shown that the helix in the N-terminal region
of smooth muscle myosin (residues 21–31) is altered in the
ADP bound state as compared to the apo state, and has been
associated with movement of the lever arm upon ADP release
(Whittaker et al., 1995). Differences have also been observed
in the structure of the SH3 domain between different isoforms
of myosin. X-ray crystallography studies found that the ﬁrst
33 amino acids of the N-terminal domain of the smooth
muscle MDE-AlF4 structure (Dominguez et al., 1998),
containing W29, fold differently than either skeletal S1
(Rayment et al., 1993) or the D. discoideum motor domain
(Fisher et al., 1995). These structural differences at least in
part reﬂect sequence variations between isoforms as the
N-terminus of myosin is not highly conserved. However,
such structural differences may also have important func-
tional implications. For example, in the skeletal muscle myo-
sin structure (Rayment et al., 1993), theN-terminal residues of
the myosin heavy chain interact with the ELC, which may
help stabilize the position of the lever arm in the postpower
stroke state. Conversely, the ELC makes contacts with the
25K-50K loop near the active site rather than the N-terminal
residues of the ADP  AlF4 smooth muscle myosin structure,
thought to be in a prepower stroke state (Dominguez et al.,
1998). Furthermore, the N-terminal residues are disordered in
a structure of smoothmusclemyosin lacking the lever arm and
ELC, but form a loosely structured loop in the presence of
a truncated lever arm including the ELC (Dominguez et al.,
1998). Our results directly demonstrate, in solution, the
conformational sensitivity of this region of the smooth mus-
cle myosin molecule. Thus, evidence is growing for the
functional signiﬁcance of conformational changes in the
N-terminal domain of myosin, which may stabilize interac-
tions of the myosin heavy chain with the ELC, and therefore
different positions of the lever arm. The unique spectroscopic
signal of W29 upon nucleotide binding should provide
a powerful tool for further elucidating structural changes in
the N-terminus of smooth muscle myosin associated with
speciﬁc states of the ATPase cycle.
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